Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat

Am J Physiol. 1995 Jan;268(1 Pt 1):L95-100. doi: 10.1152/ajplung.1995.268.1.L95.

Abstract

Exposure to hypoxia is associated with increased pulmonary artery pressure and plasma endothelin-1 (ET-1) levels and with selective enhancement in ET-1 peptide and mRNA and endothelin-A (ETA) receptor mRNA levels in rat lung. The current study tested the hypothesis that endogenous ET-1 can account for hypoxia-induced pulmonary hypertension via a paracrine effect on ETA receptors in lung. Intravenous infusion of the ETA receptor antagonist BQ-123 (D-Trp-D-Asp-Pro-D-Val-Leu) (0.4 mg/microliters at 1 microliter/h) into Sprague-Dawley rats beginning 4 h before and for 90 min during normobaric hypoxia (10% O2) markedly attenuated the hypoxic response: mean pulmonary artery pressure increased from 17.2 +/- 0.7 to 29.0 +/- 1.2 mmHg in saline control rats but did not increase from baseline in BQ-123-treated rats. BQ-123 did not alter systemic arterial pressure, heart rate, or plasma endothelin-1 levels. These findings suggest that ET-1 synthesized in lung in response to hypoxia acts locally on ETA receptors to cause pulmonary hypertension.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Disease
  • Animals
  • Blood Pressure / drug effects
  • Endothelin Receptor Antagonists*
  • Heart Rate / drug effects
  • Hypertension, Pulmonary / prevention & control*
  • Hypoxia / complications*
  • Male
  • Peptides, Cyclic / pharmacology*
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / physiopathology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Endothelin A

Substances

  • Endothelin Receptor Antagonists
  • Peptides, Cyclic
  • Receptor, Endothelin A
  • cyclo(Trp-Asp-Pro-Val-Leu)